Glycogen storage diseases (GSDs) are a group of inherited conditions in which the body can’t properly store or break down glycogen, the form of sugar your cells keep on hand for energy. There are more than a dozen types, each caused by a different missing or malfunctioning enzyme in the glycogen pathway. Some types primarily affect the liver, causing dangerously low blood sugar and an enlarged liver. Others target the muscles, leading to weakness, cramping, and exercise intolerance. A few affect both.
How Glycogen Normally Works
Your body converts glucose from food into glycogen and stores it mainly in the liver and muscles. Between meals, the liver breaks glycogen back down into glucose and releases it into the bloodstream to keep your brain and organs fueled. Muscles use their own glycogen stores during physical activity. This cycle depends on a chain of enzymes, each handling one step of building up or breaking down glycogen. When any one of those enzymes is missing or defective, glycogen either accumulates in tissues where it causes damage or can’t be converted back into usable glucose when the body needs it.
The Main Types
GSDs are numbered by type, and each one involves a different enzyme defect. The most commonly discussed types are I through V, though rarer forms exist.
Type I (von Gierke disease) affects the liver’s ability to release glucose into the bloodstream. The enzyme responsible for the final step of glucose production is missing or its transport system doesn’t work. This makes the liver the primary organ involved, leading to severe low blood sugar during fasting, an enlarged liver, elevated blood fats, and high uric acid levels. About 46% of adults with GSD type I have short stature. Over time, a major concern is the development of liver growths called hepatocellular adenomas, which carry a risk of bleeding and, in some cases, transformation into liver cancer.
Type II (Pompe disease) is different from most other GSDs because the problem is inside a specific compartment of the cell called the lysosome. Without the enzyme that breaks down glycogen there, it builds up in muscle tissue throughout the body. In infants, this causes severe heart enlargement and muscle weakness that can be life-threatening within the first year. In older children and adults, the disease progresses more slowly, primarily causing progressive muscle weakness, especially in the trunk and legs, along with breathing difficulties.
Type III (Cori or Forbes disease) involves a defective debranching enzyme. Glycogen gets only partially broken down, and the abnormal remnants accumulate in the liver and, in most cases, the muscles as well. Children typically present with an enlarged liver and low blood sugar, similar to type I but generally milder. Over time, liver scarring and cirrhosis can develop. When muscles are involved (type IIIa), patients may experience progressive weakness and, in some cases, heart muscle thickening.
Type IV (Andersen disease) is rare, accounting for about 3% of all GSDs and occurring in roughly 1 in 600,000 to 800,000 people worldwide. The branching enzyme is defective, so the body produces an abnormally structured form of glycogen that the liver treats almost like a foreign substance. The classic form causes rapidly progressive liver disease in infancy, often leading to cirrhosis. Other forms can present later in life with muscle or nervous system problems.
Type V (McArdle disease) affects only skeletal muscle. The muscle-specific enzyme that initiates glycogen breakdown is missing. The hallmark is exercise intolerance: muscle cramps, pain, and fatigue within minutes of activity. Many people with McArdle disease experience a “second wind” phenomenon, where after a brief rest, exercise becomes easier as the body shifts to burning fats and blood sugar instead. Intense exertion can cause muscle breakdown severe enough to turn urine dark brown, a sign of a potentially dangerous condition called rhabdomyolysis.
How GSD Is Diagnosed
Diagnosis starts with recognizing a pattern of symptoms and lab findings. In liver types, blood work often shows low blood sugar alongside elevated lactic acid, uric acid, cholesterol, and triglycerides. In muscle types, an enzyme called creatine kinase is typically elevated, reflecting ongoing muscle damage.
Genetic testing has largely replaced the need for tissue biopsies in confirming a diagnosis. A blood sample can be analyzed for mutations in the specific gene associated with each GSD type. In some cases, testing is guided by the patient’s ethnic background, since certain mutations are more common in specific populations. When genetic results are inconclusive, a liver biopsy with enzyme activity measurement can still be used as a definitive test for the hepatic forms.
Managing Liver Types With Diet
For types that affect the liver, the central goal of treatment is preventing blood sugar from dropping too low. The cornerstone for decades has been uncooked cornstarch, which acts as a slow-release source of glucose. Mixed with water or a sugar-free drink until fully dissolved, cornstarch is consumed every three to five hours, including overnight. Spacing doses beyond five hours doesn’t work well no matter how much cornstarch is taken, because the body’s counter-regulatory hormones kick in and drive up triglycerides and lactic acid.
Infants under six months who can’t tolerate cornstarch need glucose feedings every one and a half to two and a half hours. Older children typically move to five or six cornstarch feedings per day. Precision matters: current guidelines recommend weighing the cornstarch on a gram scale rather than using tablespoon measurements, which are less accurate. The cornstarch should be stored in a sealed container at room temperature and used within a month of opening.
For GSD type III, the dietary picture is more nuanced. The traditional approach of frequent high-carbohydrate meals and cornstarch works for preventing low blood sugar, but there’s a catch: flooding the body with carbohydrates can trigger insulin spikes that actually drive more abnormal glycogen into already-damaged muscles and liver. Recent evidence suggests that shifting to a lower-carbohydrate, higher-fat, higher-protein diet may reduce muscle damage without increasing the risk of low blood sugar. In one case study of a 24-year-old patient with severe muscle and heart involvement, gradually reducing carbohydrates from 61% to 32% of total calories while increasing healthy fats to 45% proved safe and effective. The focus is on low-glycemic-index carbohydrates and unsaturated fats to protect long-term heart and metabolic health.
Treating Pompe Disease
Pompe disease (type II) stands apart because it has a specific medical treatment: enzyme replacement therapy. Patients receive infusions of a lab-made version of the missing enzyme, which cells absorb through receptors on their surface. Once inside the cell, the replacement enzyme travels to the lysosome and breaks down the accumulated glycogen.
The results have been most dramatic for the heart. In clinical studies of infants, all patients showed significant reduction in heart size during treatment. In one study of 18 infants, all survived past 52 weeks of therapy, 15 were free of ventilator support, and 13 showed improved motor development. Three of those children learned to walk independently, a milestone that untreated infants with Pompe disease never reach.
Skeletal muscle has proven harder to treat. The enzyme doesn’t penetrate muscle tissue as effectively as it does the heart. In late-onset patients, a three-year follow-up showed that lung function stabilized and fatigue decreased, but smaller muscle groups responded better than the large proximal muscles of the hips and shoulders. The best outcomes were seen in the youngest patient who started treatment earliest, reinforcing that early diagnosis makes a real difference.
Long-Term Outlook
Life expectancy for people with GSD, particularly type I, has improved dramatically over the past 30 years. Before uncooked cornstarch therapy became standard, children with severe forms frequently suffered brain damage from repeated episodes of dangerously low blood sugar. Current standards of care largely prevent these crises, and most patients today complete regular education and hold jobs without intellectual disability.
That said, long-term complications still require lifelong monitoring. In GSD type I, liver adenomas need regular imaging to watch for growth or malignant changes. Kidney dysfunction, bone thinning, and anemia can develop over time. In type Ib specifically, immune system problems including low white blood cell counts and inflammatory bowel symptoms add another layer of complexity. For types affecting muscle, progressive weakness and heart involvement require ongoing cardiac and neurological follow-up.
Gene therapy is now in clinical trials. Programs for both Pompe disease and GSD type Ia are testing viral vectors designed to deliver a working copy of the defective gene directly to affected tissues. GSD type Ia trials have advanced to Phase III, and Pompe disease gene therapy is in Phase I, both evaluating safety and whether the approach can reduce or eliminate the need for current treatments.